NCT04706936

Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 25 (estimated)
• Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study evaluates the safety and efficacy of novel BCMA-targeted CAR-T cell therapy (CBG-002) for patients with relapsed or refractory multiple myeloma (r/r MM). CBG-002 is designed based on the fourth-generation of CAR-T techonology.

Conditions

• Relapsed or Refractory Multiple Myeloma

Interventions

Type	Name	Description
BIOLOGICAL	anti-BCMA CAR-T	Retroviral vector-transduced autologous T cells to express anti-BCMA CAR.
DRUG	Cyclophosphamid	300mg/m2/d
DRUG	Fludarabine	30mg/m2/d

Timeline

• Start date: 2021-04-01
• Primary completion: 2023-10-01
• Completion: 2024-04-01
• First posted: 2021-01-13
• Last updated: 2023-02-06

Locations

1 site across 1 country: China